Therapeutic | Enoblituzumab |
Target | CD276 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS |
Light Chain | DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2017 |
Companies Involved | MacroGenics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Conditions Approved | na |
Conditions Active | Prostate cancer, Solid tumours, Malignant melanoma, Non-small cell lung cancer, Squamous cell cancer, Urogenital cancer |
Conditions Discontinued | na |
Notes |